These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
815 related articles for article (PubMed ID: 21182349)
1. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349 [TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. Moeremans K; Annemans L; Löthgren M; Allegri G; Wyffels V; Hemmet L; Caekelbergh K; Smets E Pharmacoeconomics; 2010; 28 Suppl 1():107-28. PubMed ID: 21182347 [TBL] [Abstract][Full Text] [Related]
3. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial. Brogan A; Mauskopf J; Talbird SE; Smets E Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348 [TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Mauskopf J; Brogan A; Martin S; Smets E Pharmacoeconomics; 2010; 28 Suppl 1():83-105. PubMed ID: 21182346 [TBL] [Abstract][Full Text] [Related]
5. Darunavir: a review of its use in the management of HIV infection in adults. McKeage K; Perry CM; Keam SJ Drugs; 2009; 69(4):477-503. PubMed ID: 19323590 [TBL] [Abstract][Full Text] [Related]
6. Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER. Hill AM; Gebo K; Hemmett L; Löthgren M; Allegri G; Smets E Pharmacoeconomics; 2010; 28 Suppl 1():169-81. PubMed ID: 21182350 [TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US. Simpson KN; Jones WJ; Rajagopalan R; Dietz B Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124 [TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Simpson KN; Jones WJ; Rajagopalan R; Dietz B Clin Drug Investig; 2007; 27(12):807-17. PubMed ID: 18020538 [TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada. Brogan AJ; Smets E; Mauskopf JA; Manuel SA; Adriaenssen I Pharmacoeconomics; 2014 Sep; 32(9):903-17. PubMed ID: 24906477 [TBL] [Abstract][Full Text] [Related]
10. A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection. Mauskopf J; Annemans L; Hill AM; Smets E Pharmacoeconomics; 2010; 28 Suppl 1():1-16. PubMed ID: 21182340 [TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Simpson KN; Luo MP; Chumney EC; King MS; Brun S Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581 [TBL] [Abstract][Full Text] [Related]
12. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905 [TBL] [Abstract][Full Text] [Related]
13. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience. Hill AM; Clotet B; Johnson M; Stoll M; Bellos N; Smets E Pharmacoeconomics; 2010; 28 Suppl 1():69-81. PubMed ID: 21182345 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861 [TBL] [Abstract][Full Text] [Related]
15. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age. Möller J; Desai K; Simpson K; Baran RW; Van de Steen O; Dietz B; Gooch K J Med Econ; 2014 Apr; 17(4):250-8. PubMed ID: 24351091 [TBL] [Abstract][Full Text] [Related]
16. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN. Bánhegyi D; Katlama C; da Cunha CA; Schneider S; Rachlis A; Workman C; De Meyer S; Vandevoorde A; Van De Casteele T; Tomaka F Curr HIV Res; 2012 Mar; 10(2):171-81. PubMed ID: 22339125 [TBL] [Abstract][Full Text] [Related]
17. Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France. Colin X; Lafuma A; Costagliola D; Smets E; Mauskopf J; Guillon P Pharmacoeconomics; 2010; 28 Suppl 1():183-97. PubMed ID: 21182351 [TBL] [Abstract][Full Text] [Related]
18. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650 [TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States. Broder MS; Chang EY; Bentley TG; Juday T; Uy J J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058 [TBL] [Abstract][Full Text] [Related]
20. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. Simpson KN; Pei PP; Möller J; Baran RW; Dietz B; Woodward W; Migliaccio-Walle K; Caro JJ Pharmacoeconomics; 2013 May; 31(5):427-44. PubMed ID: 23620210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]